Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 8 Breast 8 Lymphoid 6 Genitourinary 6 Gastrointestinal 6 Tumor-Agnostic 5 Thoracic 4 Plasma cell 4 Other solid neoplasm 4 Head & Neck 4 Gynecologic 4 CNS 2 Sarcoma 1 Myeloid 1 Dermatologic 1

Conditions

Interventions

pembrolizumab 157 Nivolumab 132 Ipilimumab 77 Cyclophosphamide 46 Specimen Handling 44 Magnetic Resonance Spectroscopy 39 cemiplimab 35 Biopsy 31 fludarabine 28 trametinib 24 relatlimab 24 binimetinib 23 Interleukin-2 21 fludarabine phosphate 20 dabrafenib 20 atezolizumab 20 Radiotherapy 20 Opdualag 19 Radiosurgery 18 CTLA-4 Antigen 18 encorafenib 17 aldesleukin 17 Blood Specimen Collection 17 avelumab 14 Immunoglobulin G 14 Disulfides 13 lenvatinib 11 Bevacizumab 11 lifileucel 10 Paclitaxel 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Palliative Care × Dermatologic × 1 year × Clear all

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡